Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?

BACKGROUND: Long‐acting somatostatin analogs (SSAs) are the primary first‐line treatment of well‐differentiated advanced gastroenteropancreatic neuroendocrine tumors (NETs), but data about their efficacy in pancreatic NETs (panNETs) with Ki‐67 ≥10% are still limited. MATERIALS AND METHODS: To assess...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Merola, Elettra, Alonso Gordoa, Teresa, Zhang, Panpan, Al‐Toubah, Taymeyah, Pellè, Eleonora, Kolasińska‐Ćwikła, Agnieszka, Zandee, Wouter, Laskaratos, Faidon, de Mestier, Louis, Lamarca, Angela, Hernando, Jorge, Cwikla, Jaroslaw, Strosberg, Jonathan, de Herder, Wouter, Caplin, Martin, Cives, Mauro, van Leeuwaarde, Rachel
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2020
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018333/
https://ncbi.nlm.nih.gov/pubmed/33301235
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13633
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi